Cargando…
The Effect of Oral Propranolol versus Oral Corticosteroids in Management of Pediatric Hemangiomas
BACKGROUND: Hemangiomas are the most common benign tumors of infancy. This study evaluated the efficacy of oral propranolol comparing to oral steroids in management of pediatric hemangiomas. METHODS: In North India from January 2012 to January 2015, sixty children <6 years old with superficial he...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iranian Society for Plastic Surgeons
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890362/ https://www.ncbi.nlm.nih.gov/pubmed/29651388 |
_version_ | 1783312858472251392 |
---|---|
author | Ali, Adil Aiman, Umme Haseen, Mohd Azam Mir, Mohd Altaf Ghani, Imran Bharadwaj, Ragya Yaseen, Mohd |
author_facet | Ali, Adil Aiman, Umme Haseen, Mohd Azam Mir, Mohd Altaf Ghani, Imran Bharadwaj, Ragya Yaseen, Mohd |
author_sort | Ali, Adil |
collection | PubMed |
description | BACKGROUND: Hemangiomas are the most common benign tumors of infancy. This study evaluated the efficacy of oral propranolol comparing to oral steroids in management of pediatric hemangiomas. METHODS: In North India from January 2012 to January 2015, sixty children <6 years old with superficial hemangiomas were divided into 2 groups; oral propranolol vs. oral prednisolone. All participants were assessed for electrocardiogram, heart rate, blood pressure and sugar and initial therapy was started using 1 mg/kg and in absence of adverse effects, 2 mg/kg was administered after 2 weeks. The hemangioma Activity Score (HAS) was used for scoring and patients were followed up for 6 months. RESULTS: The propranolol group mostly showed early response to the drug and needed the drug for less time compared to corticosteroid group. In propranolol group, 16.5%, 23% and 59% needed the drug to be continued for 8-12, 4-8 and 4 months. In corticosteroid group, the therapy was continued for 8-12, and 4-8 months in 76.8% and 16.5% and in 6.6% was stopped within 4 months. In propranolol group, the response was 70% compared to 40% in other group. The mean HAS decreased significantly in propranolol group when compared to steroid group. Three patients on prednisolone developed Cushingoid features, while 1 patient in propranolol group had mild flue like symptoms. CONCLUSION: Two mg/kg of oral propranolol significantly decreased HAS, when compared to oral prednisolone, with good parent satisfaction, minimal adverse effects and no recurrence/relapse of hemangiomas after a follow up period of 6 months. |
format | Online Article Text |
id | pubmed-5890362 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Iranian Society for Plastic Surgeons |
record_format | MEDLINE/PubMed |
spelling | pubmed-58903622018-04-12 The Effect of Oral Propranolol versus Oral Corticosteroids in Management of Pediatric Hemangiomas Ali, Adil Aiman, Umme Haseen, Mohd Azam Mir, Mohd Altaf Ghani, Imran Bharadwaj, Ragya Yaseen, Mohd World J Plast Surg Original Article BACKGROUND: Hemangiomas are the most common benign tumors of infancy. This study evaluated the efficacy of oral propranolol comparing to oral steroids in management of pediatric hemangiomas. METHODS: In North India from January 2012 to January 2015, sixty children <6 years old with superficial hemangiomas were divided into 2 groups; oral propranolol vs. oral prednisolone. All participants were assessed for electrocardiogram, heart rate, blood pressure and sugar and initial therapy was started using 1 mg/kg and in absence of adverse effects, 2 mg/kg was administered after 2 weeks. The hemangioma Activity Score (HAS) was used for scoring and patients were followed up for 6 months. RESULTS: The propranolol group mostly showed early response to the drug and needed the drug for less time compared to corticosteroid group. In propranolol group, 16.5%, 23% and 59% needed the drug to be continued for 8-12, 4-8 and 4 months. In corticosteroid group, the therapy was continued for 8-12, and 4-8 months in 76.8% and 16.5% and in 6.6% was stopped within 4 months. In propranolol group, the response was 70% compared to 40% in other group. The mean HAS decreased significantly in propranolol group when compared to steroid group. Three patients on prednisolone developed Cushingoid features, while 1 patient in propranolol group had mild flue like symptoms. CONCLUSION: Two mg/kg of oral propranolol significantly decreased HAS, when compared to oral prednisolone, with good parent satisfaction, minimal adverse effects and no recurrence/relapse of hemangiomas after a follow up period of 6 months. Iranian Society for Plastic Surgeons 2018-01 /pmc/articles/PMC5890362/ /pubmed/29651388 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Ali, Adil Aiman, Umme Haseen, Mohd Azam Mir, Mohd Altaf Ghani, Imran Bharadwaj, Ragya Yaseen, Mohd The Effect of Oral Propranolol versus Oral Corticosteroids in Management of Pediatric Hemangiomas |
title | The Effect of Oral Propranolol versus Oral Corticosteroids in Management of Pediatric Hemangiomas |
title_full | The Effect of Oral Propranolol versus Oral Corticosteroids in Management of Pediatric Hemangiomas |
title_fullStr | The Effect of Oral Propranolol versus Oral Corticosteroids in Management of Pediatric Hemangiomas |
title_full_unstemmed | The Effect of Oral Propranolol versus Oral Corticosteroids in Management of Pediatric Hemangiomas |
title_short | The Effect of Oral Propranolol versus Oral Corticosteroids in Management of Pediatric Hemangiomas |
title_sort | effect of oral propranolol versus oral corticosteroids in management of pediatric hemangiomas |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890362/ https://www.ncbi.nlm.nih.gov/pubmed/29651388 |
work_keys_str_mv | AT aliadil theeffectoforalpropranololversusoralcorticosteroidsinmanagementofpediatrichemangiomas AT aimanumme theeffectoforalpropranololversusoralcorticosteroidsinmanagementofpediatrichemangiomas AT haseenmohdazam theeffectoforalpropranololversusoralcorticosteroidsinmanagementofpediatrichemangiomas AT mirmohdaltaf theeffectoforalpropranololversusoralcorticosteroidsinmanagementofpediatrichemangiomas AT ghaniimran theeffectoforalpropranololversusoralcorticosteroidsinmanagementofpediatrichemangiomas AT bharadwajragya theeffectoforalpropranololversusoralcorticosteroidsinmanagementofpediatrichemangiomas AT yaseenmohd theeffectoforalpropranololversusoralcorticosteroidsinmanagementofpediatrichemangiomas AT aliadil effectoforalpropranololversusoralcorticosteroidsinmanagementofpediatrichemangiomas AT aimanumme effectoforalpropranololversusoralcorticosteroidsinmanagementofpediatrichemangiomas AT haseenmohdazam effectoforalpropranololversusoralcorticosteroidsinmanagementofpediatrichemangiomas AT mirmohdaltaf effectoforalpropranololversusoralcorticosteroidsinmanagementofpediatrichemangiomas AT ghaniimran effectoforalpropranololversusoralcorticosteroidsinmanagementofpediatrichemangiomas AT bharadwajragya effectoforalpropranololversusoralcorticosteroidsinmanagementofpediatrichemangiomas AT yaseenmohd effectoforalpropranololversusoralcorticosteroidsinmanagementofpediatrichemangiomas |